Relationship between cortisol increment and basal cortisol: implications for the low-dose short adrenocorticotropic hormone stimulation test.
Previous studies have evaluated the operating characteristics of the LDST in adult patients with normal and abnormal adrenal function. On the basis of the results of these studies, a serum cortisol concentration of 500 nmol/L (18 [micro] g/dL) or higher (12,13), before or after low-dose ACTH injection, is suggested to be indicative of normal adrenal function. Although retrospective analysis of the HDST in a large adult population showed a marked interdependence of the basal cortisol concentration, peak cortisol concentration, and increases in serum cortisol concentration (14), criteria that require a minimum increment in serum cortisol (13) are considered invalid because individuals who have a lower basal serum cortisol concentration because of recent ACTH deficiency may be maximally stimulated by the HDST and thus able to further increase cortisol secretion. The increment with a more physiologic (1 [micro] g) dose may be expected to correlate better with the degree of adrenal stimulation. Persons with high-normal basal serum cortisol concentration may therefore have little or no increase after ACTH stimulation, whereas those with low-normal basal serum cortisol may have a maximal increase. With the HDST, however, this increase may still occur if the HPA axis is compromised. We therefore decided to investigate the relationship between the peak and basal cortisol values after the LDST.
We studied 17 patients (14 females and 3 males; age range, 18-46 years) with suspected primary adrenal dysfunction that was subsequently ruled out via a normal cortisol response on the HDST. The patients were followed in the endocrinology clinic and underwent ACTH stimulation testing to exclude 21-hydroxylase deficiency and primary adrenal dysfunction suspected in the presence of other autoimmune disorders (such as hypothyroidism or diabetes mellitus). No patient was suspected of having ACTH deficiency, and none of the female patients was pregnant or taking oral contraceptives. Each patient was tested with the HDST, and if a normal result was obtained [peak >550 nmol/L (20 [micro] g/dL)], then (within 1-2 weeks) with the LDST. We prepared low-dose (1 /xg) ACTH in 2-mL aliquots with one 250-[micro] g vial of Synacthen diluted in 500 mL of sterile normal saline solution. We obtained patient serum samples at 0, 20, 30, and 60 min after ACTH administration for the LDST. Each serum sample was separated and preserved in deep freezer at -20[degrees]C in the laboratory until analysis. Plasma cortisol was determined by the DSL-2100 cortisol-coated tube RIA (DSL). The study was done after we obtained informed consent from all participants.
The basal cortisol concentrations varied widely (Fig. 1A), from 149 to 685 nmol/L (5.4-24.8 [micro]g/dL); the mean (SD) concentration was 422.4 (138.2) nmol/L. The stimulated cortisol correlated inversely and linearly with basal cortisol, and the best correlation between basal and stimulated cortisol was at 30 min, with a linear relationship between the proportional increase in cortisol (30-min cortisol/basal cortisol) and the basal cortisol (Fig. 1B). The 95% prediction limits obtained by linear regression analysis are shown in Fig. 1B, and the cutoff for the lower 95% prediction limit at a stimulated /basal ratio of 1 was ~400 nmol/L (14.5 [micro] g/dL).
The false-negative rate for the LDST has been reported to be close to zero at cutoffs above 500-550 nmol/L (18-20 [micro] g/dL) (4,5,7,15-17). The LDST has also been advocated as a more sensitive test for ACTH deficiency than the HDST (18), but use of the same cutoff points for the LDST and HDST would serve to increase the apparent sensitivity of the LDST because peak cortisol responses are less after 1 [micro] g than 250 [micro] g of ACTH (19). At this cutoff point, however, false-positive rates are high, leading to low specificity (19).
We demonstrate here that the cortisol increment after LDST is inversely related to the basal cortisol, strongly suggesting that the peak cortisol depends on the state of adrenal stimulation at the time of the test. False poitivity occurs because in many patients peak cortisol concentrations <500-550 nmol/L (18-20 [micro] g/dL) represent normal variability, which has a wide range in humans, and not adrenal insufficiency. The incremental response to 1 [micro] g of ACTH, however, is directly and inversely dependent on basal cortisol concentrations, decreasing to zero at a mean basal cortisol concentration of 600 nmol/L (21.7 [micro] g/dL; Fig. 1B).
When devising a screening test, one aims for maximum sensitivity in the face of a reasonable specificity-in other words, excluding false negatives without including too many false positives. However, as is clear from Fig. 113, with the LDST, the lowest basal cortisol concentration at which no increment may occur after stimulation is 400 nmol/L (14.5 [micro] g/dL). This characteristic indicates that 100% sensitivity will be associated with markedly poor specificity, limiting the use of the LDST in this way. We therefore suggest that the lower 95% confidence interval for the basal cortisol at which the increment is zero be taken as the cutoff value associated with zero false positives. Any value <400 nmol/L (14.5 [micro] g/dL) after LDST will therefore be abnormal. Any value above this and up to 600 nmol/L (21.7 [micro] g/dL), our mean value at zero increment, needs a confirmatory test such as 11H or overnight metyrapone testing because the false-negative rate could be as high as 50% (19). Above 600 nmol/L (21.7 /xg/dL), the test result is highly specific and need not be confirmed. Our gray zone is wide because of our small sample size; thus we recommend that this analysis be repeated with a larger sample size to obtain a more definitive gray zone with a lower upper limit.
[FIGURE 1 OMITTED]
(1.) Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992;75:259-64.
(2.) Soule SG, Fahie-Wilson M, Tomlinson S. Failure of the short ACTH test to unequivocally diagnose long-standing symptomatic secondary hypoadrenalism. Clin Endocrinol (Oxf) 1996;44:137-40.
(3.) Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996;81:285-90.
(4.) Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab 1995;80:1301-5.
(5.) Rasmuson S, Olsson T, Hagg E. A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1996;44: 151-6.
(6.) Talwar V, Lodha S, Dash RJ. Assessing the hypothalamo-pituitary-adrenocortical axis using physiological doses of adrenocorticotropic hormone. QJM 1998;91:285-90.
(7.) Weintrob N, Sprecher E, Josefsberg Z, Weininger C, Aurbach-Klipper Y, Lazard D, et al. Standard and low-dose short adrenocorticotropin test compared with insulin-induced hypoglycemia for assessment of the hypothalamic-pituitary-adrenal axis in children with idiopathic multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 1998;83:88-92.
(8.) Rose SR, Lustig RH, Burstein S, Pitukcheewanont P, Broome DC, Burghen GA. Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. Horm Res 1999;52:73-9.
(9.) Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N. Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000;52:633-40.
(10.) Laureti S, Candeloro P, Aglietti MC, Giordano R, Arvat E, Ghigo E, et al. Dehydroepiandrosterone, 17a-hydroxyprogesterone and aldosterone responses to the low-dose (1 micro g) ACTH test in subjects with preclinical adrenal autoimmunity. Clin Endocrinol (Oxf) 2002;57:677-83.
(11.) Laureti S, Arvat E, Candeloro P, Di Vito L, Ghigo E, Santeusanio F, et al. Low dose (1 Pg) ACTH test in the evaluation of adrenal dysfunction in preclinical Addison's disease. Clin Endocrinol (Oxf) 2000;53:107-15.
(12.) Bhansali A, Subrahmanyam KA, Talwar V, Dash RJ. Plasma cortisol response to 1 microgram adrenocorticotropin at 0800 h & 1600 h in healthy subjects. Indian J Med Res 2001;114:173-6.
(13.) Dickstein G. Hypothalamo-pituitary-adrenal axis testing: nothing is sacred and caution in interpretation is needed. Clin Endocrinol (Oxf) 2001;54: 15-6.
(14.) May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med 1985;79:679-84.
(15.) Ambrosi B, Barbetta L, Re T, Passini E, Faglia G. The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function. Eur J Endocrinol 1998;139:575-9.
(16.) Mayenknecht J, Diederich S, Bahr V, Plockinger U, Oelkers W. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab 1998;83:1558-62.
(17.) Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short Synacthen test (1 microg), the conventional dose short Synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamopituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 1999;84:838-43.
(18.) Patel L, Clayton PE. Clinical usefulness of the low dose ACTH test. J Endocrinol Invest 1999;22:401-4.
(19.) Soule S, Van Zyl Smit C, Parolis G, Attenborough S, Peter D, Kinvig S, et al. The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism. Clin Endocrinol (Oxf) 2000;53:221-7.
Previously published online at DOI: 10.1373/clinchem.2005.061267
Suhail A.R. Doi,[1 *] Ibrahim Lasheen,  Khaldoon Al-Humood,  and Kamal A.S. Al-Shoumerl 
(Divisions of  Endocrinology and  Medicine, Mubarak Al Kabeer Teaching Hospital, Jabriya, Kuwait; * address correspondence to this author at: Division of Endocrinology, Mubarak Al Kabeer Teaching Hospital, PO Box 64849 Shuwaikh, 70459 Kuwait; fax 44-709-2377990, e-mail firstname.lastname@example.org)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||Doi, Suhail A.R.; Lasheen, Ibrahim; Al-Humood, Khaldoon; Al-Shoumer, Kamal A.S.|
|Date:||Apr 1, 2006|
|Previous Article:||Differentiation of amphetamine/methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing.|
|Next Article:||Total polyphenol intake estimated by a modified folin-ciocalteu assay of urine.|